<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01125605</url>
  </required_header>
  <id_info>
    <org_study_id>174A10PNAL</org_study_id>
    <nct_id>NCT01125605</nct_id>
  </id_info>
  <brief_title>PASCONAL NERVENTROPFEN in the Treatment of Nervous Diseases</brief_title>
  <acronym>174</acronym>
  <official_title>PASCONAL NERVENTROPFEN in the Treatment of Adults and Children Suffering From Nervous Diseases (e.g. Sleep Disorders Due to Nervousness)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pascoe Pharmazeutische Praeparate GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pascoe Pharmazeutische Praeparate GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to give an overview of the use of PASCONAL
      NERVENTROPFEN in a 2-4 week treatment of nervous diseases, especially sleep disorders due to
      nervousness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this observational study is to give an overview of the use of PASCONAL
      NERVENTROPFEN in a 2-4 week treatment of nervous diseases, especially sleep disorders due to
      nervousness.

      Efficacy and tolerability of the drug will be assessed. Special regard will be taken to the
      administration management, dose regimen, and to the effectiveness and safety in special
      patient groups (children 1-12 years of age), in relation to treatment conformity to the
      Summary of Product Characteristics (SmPC).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sumscore of 12 Individual Symptoms for Visit 1 (Baseline), Visit 2, and Visit 3</measure>
    <time_frame>begin (visit 1), appr. after 2 weeks (visit 2), and appr. after 4 weeks (visit 3)</time_frame>
    <description>The severity of 12 symptoms (nervousness/restlessness, irritability/eccentricity, sleep disorders, fitful sleep, hyperactivity, nocturnal activity, lack of concentration/forgetfulness, tiredness, discontent, listlessness, gastrointestinal problems, and headache/pressure) was graded on a four-point scale from 0 (no complaints) to 3 (strong complaints) and for the sum score of all 12 individual symptom scores (0 (no complaints) - 36 (all strong complaints).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nervousness/Restlessness for Visit 1 (Baseline), Visit 2, Visit 3 and Last Obsevation</measure>
    <time_frame>begin (visit 1), appr. after 2 weeks (visit 2), and appr. after 4 weeks (visit 3)</time_frame>
    <description>The severity of nervousness/restlessness was graded on a four-point scale from 0 (no complaints) to 3 (strong complaints).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Irritability/Eccentricity for Visit 1 (Baseline), Visit 2, Visit 3 and Last Observation</measure>
    <time_frame>begin (visit 1), appr. after 2 weeks (visit 2), and appr. after 4 weeks (visit 3)</time_frame>
    <description>The severity of irritability/eccentricity was graded on a four-point scale from 0 (no complaints) to 3 (strong complaints).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability After Visit 2 and Visit 3</measure>
    <time_frame>appr. after 2 weeks (visit 2), and appr. after 4 weeks (visit 3)</time_frame>
    <description>Assessment of tolerability at visit 2 and visit 3 well tolerated = no side effcts poor tolerated = side effects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of the Sum Score Between Baseline and Last Observation by Concomitant Medication and Treatment Duration</measure>
    <time_frame>begin (visit 1) and last obvservation (could be appr. after 2 weeks (visit 2) or 4 weeks (visit 3))</time_frame>
    <description>The severity of 12 symptoms (nervousness/restlessness, irritability/eccentricity, sleep disorders, fitful sleep, hyperactivity, nocturnal activity, lack of concentration/forgetfulness, tiredness, discontent, listlessness, gastrointestinal problems, and headache/pressure) was graded on a four-point scale from 0 (no complaints) to 3 (strong complaints) and for the sum score of all 12 individual symptom scores (0 (no complaints) - 36 (all strong complaints).
Decrease of the sumscore between baseline and last observation by concomitant medication (with and withour medication) and treatment duration (&lt; 4 weeks and &gt;= 4 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direction of Change of Symptom Nervousness/Restlessnes Between Baseline and Last Observation by Concomitant Medication</measure>
    <time_frame>begin (visit 1) and last observation (could be appr. after 2 weeks (visit 2) or appr. after 4 weeks (visit 3))</time_frame>
    <description>The symptom nervousness/restlessnesswas analysed with respect to the direction of change between baseline (Visit 1) and the last documented visit (Visit 2 or Visit 3) by means of the categories &quot;improved&quot;, &quot;unchanged&quot; and &quot;worsened&quot;. For each symptom patients were included in the analysis only if the symptom had been present at Visit 1 (i.e. the baseline score value was &gt; 0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direction of Change of Symptom Nervousness/Restlessnes Between Baseline and Last Observation by Duration of Treatment</measure>
    <time_frame>begin (visit 1) and last observation (could be appr. after 2 weeks (visit 2) or appr. after 4 weeks (visit 3))</time_frame>
    <description>The symptom nervousness/restlessness was analysed with respect to the direction of change between baseline (Visit 1) and the last documented visit (Visit 2 or Visit 3) by means of the categories &quot;improved&quot;, &quot;unchanged&quot; and &quot;worsened&quot;. For each symptom patients were included in the analysis only if the symptom had been present at Visit 1 (i.e. the baseline score value was &gt; 0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direction of Change of Symptom Irritability/Eccentricity Between Baseline and Last Observation by Concomitant Medication</measure>
    <time_frame>begin (visit 1) and last observation (could be appr. after 2 weeks (visit 2) or appr. after 4 weeks (visit 3))</time_frame>
    <description>The symptom irritability/eccentricity was analysed with respect to the direction of change between baseline (Visit 1) and the last documented visit (Visit 2 or Visit 3) by means of the categories &quot;improved&quot;, &quot;unchanged&quot; and &quot;worsened&quot;. For each symptom patients were included in the analysis only if the symptom had been present at Visit 1 (i.e. the baseline score value was &gt; 0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direction of Change of Symptom Irritability/Eccentricity Between Baseline and Last Observation by Duration of Treatment</measure>
    <time_frame>begin (visit 1) and last observation (appr. after 2 weeks (visit 2) or appr. after 4 weeks (visit 3))</time_frame>
    <description>The symptom irritability/eccentricity was analysed with respect to the direction of change between baseline (Visit 1) and the last documented visit (Visit 2 or Visit 3) by means of the categories &quot;improved&quot;, &quot;unchanged&quot; and &quot;worsened&quot;. For each symptom patients were included in the analysis only if the symptom had been present at Visit 1 (i.e. the baseline score value was &gt; 0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Rating for PASCONAL® NERVENTROPFEN (Last Value) Compared to Previous Therapy by Concomitant Medication (Yes/no)</measure>
    <time_frame>appr. after 2 weeks (visit 2) and appr. after 4 weeks (visit 3)</time_frame>
    <description>Efficacy of the therapy with PASCONAL® NERVENTROPFEN was rated by the physician on a 4-point rating scale at Visit 2 and Visit 3. The same scale was applied at Visit 1 for evaluation of the efficacy of the previous medication.
The last evaluation for PASCONAL® NERVENTROPFEN (Visit 2 or Visit 3, according to the LOCF principle) was compared with the rating for the previous therapy by means of the categories &quot;PASCONAL® better&quot;, &quot;No difference&quot; and &quot;PASCONAL® worse&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Rating for PASCONAL® NERVENTROPFEN (Last Value) Compared to Previous Therapy by Treatment Duration</measure>
    <time_frame>appr. after 2 weeks (visit 2) and appr. after 4 weeks (visit 3)</time_frame>
    <description>Efficacy of the therapy with PASCONAL® NERVENTROPFEN was rated by the physician on a 4-point rating scale at Visit 2 and Visit 3. The same scale was applied at Visit 1 for evaluation of the efficacy of the previous medication.
The last evaluation for PASCONAL® NERVENTROPFEN (Visit 2 or Visit 3, according to the LOCF principle) was compared with the rating for the previous therapy by means of the categories &quot;PASCONAL® better&quot;, &quot;No difference&quot; and &quot;PASCONAL® worse&quot;.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">325</enrollment>
  <condition>Nervousness</condition>
  <condition>Sleep Disorders</condition>
  <arm_group>
    <arm_group_label>Adults &gt; 12 years</arm_group_label>
    <description>adult patients and patients older than 12 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children 6-12 years</arm_group_label>
    <description>children between 6 and 12 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children 1-6 years</arm_group_label>
    <description>children between 1 and 6 years</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Observational groups

        Patients (adults and children 1-12 years of age) suffering from nervous diseases, e.g.
        sleep-disturbances due to nervousness.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Due to the design as an Observational Study no inclusion or exclusion criteria for therapy
        are named. The included patient group is described under &quot;Cohort / Group&quot;.

        Observational Criteria (=inclusion criteria for documentation):

          -  Males and females

          -  Children 1-12 years old

          -  Adults &gt;12 years old

          -  suffering from nervous diseases, e.g. sleep disorders due to nervousness.

        Exclusion criteria for documentation:

          -  children younger than 1 year

          -  no nervous diseases, e.g. sleep disorders due to nervousness.

          -  no treatment with PASCONAL NERVENTROPFEN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bianka Krick</last_name>
    <role>Study Director</role>
    <affiliation>Pascoe Pharmazeutische Praeparate GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Multiple German Practices</name>
      <address>
        <city>all over Germany</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2010</study_first_submitted>
  <study_first_submitted_qc>May 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2010</study_first_posted>
  <results_first_submitted>July 18, 2012</results_first_submitted>
  <results_first_submitted_qc>July 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 27, 2012</results_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PASCONAL</keyword>
  <keyword>nervousness</keyword>
  <keyword>nervosity</keyword>
  <keyword>sleep disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Physicians who were registered in the past with the treatment focus on central nervous system / psyche. The recruitment of the participating physicians was done by the field service of PASCOE.</recruitment_details>
      <pre_assignment_details>It was an non-inteventional observational study with 3 visits.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Observational Group</title>
          <description>Pasconal Nerventropfen PASCONAL® NERVENTROPFEN is a homoeopathic combination product (oral drops) consisting out of 4 ingredients: Avena sativa, Valeriana, Ignatia and Tarantula.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="325">started = had baseline values</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety</title>
              <participants_list>
                <participants group_id="P1" count="326">1 patient was only analysed for safety</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="325"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Observational Group</title>
          <description>Pasconal Nerventropfen</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="325"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant medication</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>with concomitant medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>without concomitant medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of disease years</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>State of inclusion diagnosis</title>
          <description>The duration of complaints was divided into two groups to the extent this was possible:
Acute disease (duration of symptoms ≤2 months)
Subchronic and/or chronic disease (duration of symptoms &gt;2 months)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>acute (&lt;= 2 months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>subchronic/chronic (&gt; 2 months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous treatment of inclusion diagnosis</title>
          <description>Within the range of the observational study, it was ascertained whether the inclusion diagnosis had been treated previously.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>with previous treatment of inclusion diagnosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>without previous treatment of inclusion diagnosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sumscore of 12 Individual Symptoms for Visit 1 (Baseline), Visit 2, and Visit 3</title>
        <description>The severity of 12 symptoms (nervousness/restlessness, irritability/eccentricity, sleep disorders, fitful sleep, hyperactivity, nocturnal activity, lack of concentration/forgetfulness, tiredness, discontent, listlessness, gastrointestinal problems, and headache/pressure) was graded on a four-point scale from 0 (no complaints) to 3 (strong complaints) and for the sum score of all 12 individual symptom scores (0 (no complaints) - 36 (all strong complaints).</description>
        <time_frame>begin (visit 1), appr. after 2 weeks (visit 2), and appr. after 4 weeks (visit 3)</time_frame>
        <population>descriptive; for all partcipations with values at the visits</population>
        <group_list>
          <group group_id="O1">
            <title>Visit 1</title>
            <description>Observational group (Pasconal Nerventropfen) at visit 1</description>
          </group>
          <group group_id="O2">
            <title>Visit 2</title>
            <description>Observational group (Pasconal Nerventropfen) at visit 2</description>
          </group>
          <group group_id="O3">
            <title>Visit 3</title>
            <description>Observational group (Pasconal Nerventropfen) at visit 3</description>
          </group>
          <group group_id="O4">
            <title>Last Observation</title>
            <description>Observational group (Pasconal Nerventropfen) at last observation</description>
          </group>
        </group_list>
        <measure>
          <title>Sumscore of 12 Individual Symptoms for Visit 1 (Baseline), Visit 2, and Visit 3</title>
          <description>The severity of 12 symptoms (nervousness/restlessness, irritability/eccentricity, sleep disorders, fitful sleep, hyperactivity, nocturnal activity, lack of concentration/forgetfulness, tiredness, discontent, listlessness, gastrointestinal problems, and headache/pressure) was graded on a four-point scale from 0 (no complaints) to 3 (strong complaints) and for the sum score of all 12 individual symptom scores (0 (no complaints) - 36 (all strong complaints).</description>
          <population>descriptive; for all partcipations with values at the visits</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="325"/>
                <count group_id="O3" value="309"/>
                <count group_id="O4" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="6.1"/>
                    <measurement group_id="O2" value="9.2" spread="5.6"/>
                    <measurement group_id="O3" value="5.1" spread="4.5"/>
                    <measurement group_id="O4" value="6.2" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of the Sum Score Between Baseline and Last Observation by Concomitant Medication and Treatment Duration</title>
        <description>The severity of 12 symptoms (nervousness/restlessness, irritability/eccentricity, sleep disorders, fitful sleep, hyperactivity, nocturnal activity, lack of concentration/forgetfulness, tiredness, discontent, listlessness, gastrointestinal problems, and headache/pressure) was graded on a four-point scale from 0 (no complaints) to 3 (strong complaints) and for the sum score of all 12 individual symptom scores (0 (no complaints) - 36 (all strong complaints).
Decrease of the sumscore between baseline and last observation by concomitant medication (with and withour medication) and treatment duration (&lt; 4 weeks and &gt;= 4 weeks)</description>
        <time_frame>begin (visit 1) and last obvservation (could be appr. after 2 weeks (visit 2) or 4 weeks (visit 3))</time_frame>
        <population>exploratively, all participations with values</population>
        <group_list>
          <group group_id="O1">
            <title>Visit 1</title>
            <description>Observational group (Pasconal Nerventropfen) at visit 1</description>
          </group>
          <group group_id="O2">
            <title>Last Observation</title>
            <description>Observational group (Pasconal Nerventropfen) at last observation</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of the Sum Score Between Baseline and Last Observation by Concomitant Medication and Treatment Duration</title>
          <description>The severity of 12 symptoms (nervousness/restlessness, irritability/eccentricity, sleep disorders, fitful sleep, hyperactivity, nocturnal activity, lack of concentration/forgetfulness, tiredness, discontent, listlessness, gastrointestinal problems, and headache/pressure) was graded on a four-point scale from 0 (no complaints) to 3 (strong complaints) and for the sum score of all 12 individual symptom scores (0 (no complaints) - 36 (all strong complaints).
Decrease of the sumscore between baseline and last observation by concomitant medication (with and withour medication) and treatment duration (&lt; 4 weeks and &gt;= 4 weeks)</description>
          <population>exploratively, all participations with values</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>with concomitant medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="5.5"/>
                    <measurement group_id="O2" value="7.7" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>without concomitant medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="6.2"/>
                    <measurement group_id="O2" value="5.8" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 4 weeks treatment duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="5.3"/>
                    <measurement group_id="O2" value="7.4" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 4 weeks treatment duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="6.2"/>
                    <measurement group_id="O2" value="5.9" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>decrease of the sum score between baseline (visit 1) and last observation was exploratively analysed</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0033</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with GLM (Generalized Linear Model) of SAS® (with type III sums of squares); including the baseline value of the sum score as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>decrease of the sum score between baseline (visit1) and last observation by duration of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with GLM (Generalized Linear Model) of SAS® (with type III sums of squares); including the baseline value of the sum score as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Direction of Change of Symptom Nervousness/Restlessnes Between Baseline and Last Observation by Concomitant Medication</title>
        <description>The symptom nervousness/restlessnesswas analysed with respect to the direction of change between baseline (Visit 1) and the last documented visit (Visit 2 or Visit 3) by means of the categories “improved”, “unchanged” and “worsened”. For each symptom patients were included in the analysis only if the symptom had been present at Visit 1 (i.e. the baseline score value was &gt; 0).</description>
        <time_frame>begin (visit 1) and last observation (could be appr. after 2 weeks (visit 2) or appr. after 4 weeks (visit 3))</time_frame>
        <population>exploratively, all participations with values</population>
        <group_list>
          <group group_id="O1">
            <title>With Concomitant Medication</title>
            <description>Observational group (Pasconal Nerventropfen) with concomitant medication</description>
          </group>
          <group group_id="O2">
            <title>Without Concomitant Medication</title>
            <description>Observational group (Pasconal Nerventropfen) without concomitant medication</description>
          </group>
        </group_list>
        <measure>
          <title>Direction of Change of Symptom Nervousness/Restlessnes Between Baseline and Last Observation by Concomitant Medication</title>
          <description>The symptom nervousness/restlessnesswas analysed with respect to the direction of change between baseline (Visit 1) and the last documented visit (Visit 2 or Visit 3) by means of the categories “improved”, “unchanged” and “worsened”. For each symptom patients were included in the analysis only if the symptom had been present at Visit 1 (i.e. the baseline score value was &gt; 0).</description>
          <population>exploratively, all participations with values</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Direction of Change of Symptom Nervousness/Restlessnes Between Baseline and Last Observation by Duration of Treatment</title>
        <description>The symptom nervousness/restlessness was analysed with respect to the direction of change between baseline (Visit 1) and the last documented visit (Visit 2 or Visit 3) by means of the categories &quot;improved&quot;, &quot;unchanged&quot; and &quot;worsened&quot;. For each symptom patients were included in the analysis only if the symptom had been present at Visit 1 (i.e. the baseline score value was &gt; 0).</description>
        <time_frame>begin (visit 1) and last observation (could be appr. after 2 weeks (visit 2) or appr. after 4 weeks (visit 3))</time_frame>
        <population>exploratively, all participations with values</population>
        <group_list>
          <group group_id="O1">
            <title>&lt; 4 Weeks</title>
            <description>Observational group (Pasconal Nerventropfen) with a treatment duration &lt; 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>&gt; = 4 Weeks</title>
            <description>Observational group (Pasconal Nerventropfen) with a treatment duration &gt;= 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Direction of Change of Symptom Nervousness/Restlessnes Between Baseline and Last Observation by Duration of Treatment</title>
          <description>The symptom nervousness/restlessness was analysed with respect to the direction of change between baseline (Visit 1) and the last documented visit (Visit 2 or Visit 3) by means of the categories &quot;improved&quot;, &quot;unchanged&quot; and &quot;worsened&quot;. For each symptom patients were included in the analysis only if the symptom had been present at Visit 1 (i.e. the baseline score value was &gt; 0).</description>
          <population>exploratively, all participations with values</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0125</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Direction of Change of Symptom Irritability/Eccentricity Between Baseline and Last Observation by Concomitant Medication</title>
        <description>The symptom irritability/eccentricity was analysed with respect to the direction of change between baseline (Visit 1) and the last documented visit (Visit 2 or Visit 3) by means of the categories &quot;improved&quot;, &quot;unchanged&quot; and &quot;worsened&quot;. For each symptom patients were included in the analysis only if the symptom had been present at Visit 1 (i.e. the baseline score value was &gt; 0).</description>
        <time_frame>begin (visit 1) and last observation (could be appr. after 2 weeks (visit 2) or appr. after 4 weeks (visit 3))</time_frame>
        <population>exploratively, all participations with values</population>
        <group_list>
          <group group_id="O1">
            <title>With Concomitant Medication</title>
            <description>Observational group (Pasconal Nerventropfen) with concomitant medication</description>
          </group>
          <group group_id="O2">
            <title>Without Concomitant Medication</title>
            <description>Observational group (Pasconal Nerventropfen) without concomitant medication</description>
          </group>
        </group_list>
        <measure>
          <title>Direction of Change of Symptom Irritability/Eccentricity Between Baseline and Last Observation by Concomitant Medication</title>
          <description>The symptom irritability/eccentricity was analysed with respect to the direction of change between baseline (Visit 1) and the last documented visit (Visit 2 or Visit 3) by means of the categories &quot;improved&quot;, &quot;unchanged&quot; and &quot;worsened&quot;. For each symptom patients were included in the analysis only if the symptom had been present at Visit 1 (i.e. the baseline score value was &gt; 0).</description>
          <population>exploratively, all participations with values</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Direction of Change of Symptom Irritability/Eccentricity Between Baseline and Last Observation by Duration of Treatment</title>
        <description>The symptom irritability/eccentricity was analysed with respect to the direction of change between baseline (Visit 1) and the last documented visit (Visit 2 or Visit 3) by means of the categories &quot;improved&quot;, &quot;unchanged&quot; and &quot;worsened&quot;. For each symptom patients were included in the analysis only if the symptom had been present at Visit 1 (i.e. the baseline score value was &gt; 0).</description>
        <time_frame>begin (visit 1) and last observation (appr. after 2 weeks (visit 2) or appr. after 4 weeks (visit 3))</time_frame>
        <population>exploratively, all participations with values</population>
        <group_list>
          <group group_id="O1">
            <title>&lt; 4 Weeks</title>
            <description>Observational group (Pasconal Nerventropfen) with a treatment duration &lt; 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>&gt; = 4 Weeks</title>
            <description>Observational group (Pasconal Nerventropfen) with a treatment duration &gt;= 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Direction of Change of Symptom Irritability/Eccentricity Between Baseline and Last Observation by Duration of Treatment</title>
          <description>The symptom irritability/eccentricity was analysed with respect to the direction of change between baseline (Visit 1) and the last documented visit (Visit 2 or Visit 3) by means of the categories &quot;improved&quot;, &quot;unchanged&quot; and &quot;worsened&quot;. For each symptom patients were included in the analysis only if the symptom had been present at Visit 1 (i.e. the baseline score value was &gt; 0).</description>
          <population>exploratively, all participations with values</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0016</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Rating for PASCONAL® NERVENTROPFEN (Last Value) Compared to Previous Therapy by Concomitant Medication (Yes/no)</title>
        <description>Efficacy of the therapy with PASCONAL® NERVENTROPFEN was rated by the physician on a 4-point rating scale at Visit 2 and Visit 3. The same scale was applied at Visit 1 for evaluation of the efficacy of the previous medication.
The last evaluation for PASCONAL® NERVENTROPFEN (Visit 2 or Visit 3, according to the LOCF principle) was compared with the rating for the previous therapy by means of the categories “PASCONAL® better”, “No difference” and “PASCONAL® worse”.</description>
        <time_frame>appr. after 2 weeks (visit 2) and appr. after 4 weeks (visit 3)</time_frame>
        <population>exploratively, all participations with values</population>
        <group_list>
          <group group_id="O1">
            <title>With Concomitant Medication</title>
            <description>Observational group (Pasconal Nerventropfen) with concomitant medication</description>
          </group>
          <group group_id="O2">
            <title>Without Concomitant Medication</title>
            <description>Observational group (Pasconal Nerventropfen) without concomitant medication</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Rating for PASCONAL® NERVENTROPFEN (Last Value) Compared to Previous Therapy by Concomitant Medication (Yes/no)</title>
          <description>Efficacy of the therapy with PASCONAL® NERVENTROPFEN was rated by the physician on a 4-point rating scale at Visit 2 and Visit 3. The same scale was applied at Visit 1 for evaluation of the efficacy of the previous medication.
The last evaluation for PASCONAL® NERVENTROPFEN (Visit 2 or Visit 3, according to the LOCF principle) was compared with the rating for the previous therapy by means of the categories “PASCONAL® better”, “No difference” and “PASCONAL® worse”.</description>
          <population>exploratively, all participations with values</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PASCONAL better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No difference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PACONAL worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0504</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Nervousness/Restlessness for Visit 1 (Baseline), Visit 2, Visit 3 and Last Obsevation</title>
        <description>The severity of nervousness/restlessness was graded on a four-point scale from 0 (no complaints) to 3 (strong complaints).</description>
        <time_frame>begin (visit 1), appr. after 2 weeks (visit 2), and appr. after 4 weeks (visit 3)</time_frame>
        <population>descriptive; for all partcipations with values at the visits</population>
        <group_list>
          <group group_id="O1">
            <title>Visit 1</title>
            <description>Observational group (Pasconal Nerventropfen) at visit 1</description>
          </group>
          <group group_id="O2">
            <title>Visit 2</title>
            <description>Observational group (Pasconal Nerventropfen) at visit 2</description>
          </group>
          <group group_id="O3">
            <title>Visit 3</title>
            <description>Observational group (Pasconal Nerventropfen) at visit 1</description>
          </group>
          <group group_id="O4">
            <title>Last Observation</title>
            <description>Observational group (Pasconal Nerventropfen) at last observation</description>
          </group>
        </group_list>
        <measure>
          <title>Nervousness/Restlessness for Visit 1 (Baseline), Visit 2, Visit 3 and Last Obsevation</title>
          <description>The severity of nervousness/restlessness was graded on a four-point scale from 0 (no complaints) to 3 (strong complaints).</description>
          <population>descriptive; for all partcipations with values at the visits</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
                <count group_id="O2" value="306"/>
                <count group_id="O3" value="293"/>
                <count group_id="O4" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0=not present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1=mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="171"/>
                    <measurement group_id="O3" value="180"/>
                    <measurement group_id="O4" value="789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2=moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3=Strong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Rating for PASCONAL® NERVENTROPFEN (Last Value) Compared to Previous Therapy by Treatment Duration</title>
        <description>Efficacy of the therapy with PASCONAL® NERVENTROPFEN was rated by the physician on a 4-point rating scale at Visit 2 and Visit 3. The same scale was applied at Visit 1 for evaluation of the efficacy of the previous medication.
The last evaluation for PASCONAL® NERVENTROPFEN (Visit 2 or Visit 3, according to the LOCF principle) was compared with the rating for the previous therapy by means of the categories &quot;PASCONAL® better&quot;, &quot;No difference&quot; and &quot;PASCONAL® worse&quot;.</description>
        <time_frame>appr. after 2 weeks (visit 2) and appr. after 4 weeks (visit 3)</time_frame>
        <population>exploratively, all participations with values</population>
        <group_list>
          <group group_id="O1">
            <title>&lt; 4 Weeks</title>
            <description>Observational group (Pasconal Nerventropfen) with concomitant medication</description>
          </group>
          <group group_id="O2">
            <title>&gt;= 4 Weeks</title>
            <description>Observational group (Pasconal Nerventropfen) without concomitant medication</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Rating for PASCONAL® NERVENTROPFEN (Last Value) Compared to Previous Therapy by Treatment Duration</title>
          <description>Efficacy of the therapy with PASCONAL® NERVENTROPFEN was rated by the physician on a 4-point rating scale at Visit 2 and Visit 3. The same scale was applied at Visit 1 for evaluation of the efficacy of the previous medication.
The last evaluation for PASCONAL® NERVENTROPFEN (Visit 2 or Visit 3, according to the LOCF principle) was compared with the rating for the previous therapy by means of the categories &quot;PASCONAL® better&quot;, &quot;No difference&quot; and &quot;PASCONAL® worse&quot;.</description>
          <population>exploratively, all participations with values</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PASCONAL better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No difference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PACONAL worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Irritability/Eccentricity for Visit 1 (Baseline), Visit 2, Visit 3 and Last Observation</title>
        <description>The severity of irritability/eccentricity was graded on a four-point scale from 0 (no complaints) to 3 (strong complaints).</description>
        <time_frame>begin (visit 1), appr. after 2 weeks (visit 2), and appr. after 4 weeks (visit 3)</time_frame>
        <population>descriptive; for all partcipations with values at the visits</population>
        <group_list>
          <group group_id="O1">
            <title>Visit 1</title>
            <description>Observational group (Pasconal Nerventropfen) at visit 1</description>
          </group>
          <group group_id="O2">
            <title>Visit 2</title>
            <description>Observational group (Pasconal Nerventropfen) at visit 2</description>
          </group>
          <group group_id="O3">
            <title>Visit 3</title>
            <description>Observational group (Pasconal Nerventropfen) at visit 1</description>
          </group>
          <group group_id="O4">
            <title>Last Observation</title>
            <description>Observational group (Pasconal Nerventropfen) at last observation</description>
          </group>
        </group_list>
        <measure>
          <title>Irritability/Eccentricity for Visit 1 (Baseline), Visit 2, Visit 3 and Last Observation</title>
          <description>The severity of irritability/eccentricity was graded on a four-point scale from 0 (no complaints) to 3 (strong complaints).</description>
          <population>descriptive; for all partcipations with values at the visits</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="278"/>
                <count group_id="O4" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0=not present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="111"/>
                    <measurement group_id="O4" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1=mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="163"/>
                    <measurement group_id="O3" value="136"/>
                    <measurement group_id="O4" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2=moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3=Strong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tolerability After Visit 2 and Visit 3</title>
        <description>Assessment of tolerability at visit 2 and visit 3 well tolerated = no side effcts poor tolerated = side effects</description>
        <time_frame>appr. after 2 weeks (visit 2), and appr. after 4 weeks (visit 3)</time_frame>
        <population>descriptive; for safety 326 patients were analysed; 1 patient had no efficacy values and were not analysed for efficacy; so a discrepancy between 325 patients (for efficacy) and 326 (for safety) occured</population>
        <group_list>
          <group group_id="O1">
            <title>Visit 2</title>
            <description>Observational group (Pasconal Nerventropfen) at visit 2</description>
          </group>
          <group group_id="O2">
            <title>Visit 3</title>
            <description>Observational group (Pasconal Nerventropfen) at visit 3</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability After Visit 2 and Visit 3</title>
          <description>Assessment of tolerability at visit 2 and visit 3 well tolerated = no side effcts poor tolerated = side effects</description>
          <population>descriptive; for safety 326 patients were analysed; 1 patient had no efficacy values and were not analysed for efficacy; so a discrepancy between 325 patients (for efficacy) and 326 (for safety) occured</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>well tolerated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="313"/>
                    <measurement group_id="O2" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>poor tolerated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>after appr. 2 weeks and after appr. 4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Observational Group</title>
          <description>Pasconal Nerventropfen</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.1</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>stomach ache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>tongue and mucosa under tongue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>tiredness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>aggressivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>Pascoe pharmazeutische Praeparate GmbH</organization>
      <phone>0049 641 7960100</phone>
      <email>klinische.forschung@pascoe.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

